학술논문
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.
Document Type
Journal Article
Author
Source
Subject
*GENETIC mutation
*DASATINIB
*IMATINIB
*TREATMENT of chronic myeloid leukemia
*NILOTINIB
*DRUG resistance
*
*
*
*
*
Language
ISSN
0887-6924